KIT and acute myeloid leukemia: Additionally, M4205 showed dose-dependent antitumor efficacy in an AML model with a KIT driver mutation in exon 17 (Kasumi-1 and N822K) with regression observed at the highest dosage of 20 mg/kg daily (Fig. 5F).